Report Links New Diabetes Drugs to Serious Side Effects
A recent report by AdverseEvents, a California company that analyzes post-market side effect data, has linked new classes of Type 2 diabetes drugs to serious side effects, including pancreatic cancer, thyroid cancer, and renal problems.
About the Diabetes Drug Study
“The only way to fully review a drug’s safety is to track and monitor side effects as the general population begins utilizing the drugs on an ongoing basis, in real-world circumstances.” – Brian Overstreet, CEO of AdverseEvents, as published by DrugWatch
In its report, “The Comparative Safety of Type 2 Diabetes Medicaitons,” AdverseEvents analyzed adverse event data for 11 diabetes medications in three different drug classes:
- GLP-1 Agonists
- DPP-4 Inhibitors
- SLGT2 Inhibitors
Using data from the FDA’s Adverse Event Reporting Systems (FAERS), AdverseEvents was able to review side effects reported by patients and doctors, determine whether these events were life threatening, and if they resulted in hospitalization, disabilities, or death.
Findings of the Diabetes Drug Study
According to the final report, all the reviewed drugs carried significant risks of side effects.
AdverseEvents determined that both GLP-1 agonists were associated with an increased risk of pancreatitis and pancreatic cancer, as well as thyroid cancers and elevated reporting of gastrointestinal issues. The organization noted that risks posed by Bydureon were consistently lower than those posed by Victoza and Byetta.
DPP-4 Inhibitors had a lower association with gastrointestinal issues than GLP-1 agonists; however, elevated signals of pancreatitis and pancreatic cancer remained. Janumet and Januvia, which contain sitagliptin, had the highest association with these risks.
Finally, AdverseEvents linked SLGT2 inhibitors to an increased risk of urinary infection and expressed concern that these drugs could result in renal and gallbladder issues in addition to bladder cancer.